Login to Your Account

Other News To Note

Monday, December 19, 2011
• Galectin Therapeutics Inc., of Newton, Mass., presented a poster at the European Association for the Study of the Liver Special Conference on Liver Transplantation in Lisbon, Portugal, showing that its galectin inhibitor candidate GR-MD-02 reversed fibrosis in mouse models of steatohepatitis and prevented collagen deposits in mice treated before fibrotic cells formed.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription